• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

    2/9/24 5:11:51 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGEN alert in real time by email
    SC 13G/A 1 d686535dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 1)

     

     

    Agenus Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

    00847G705

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 00847G705    13G   

     

    1   

    NAMES OF REPORTING PERSONS

     

    Invus Public Equities, L.P.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    15,631,235

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    15,631,235

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,631,235

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.1%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    2


    CUSIP No. 00847G705    13G   

     

    1   

    NAMES OF REPORTING PERSONS

     

    Invus Public Equities Advisors, LLC

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    15,631,235

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    15,631,235

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,631,235

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.1%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    3


    CUSIP No. 00847G705    13G   

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal International S.C.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    15,631,235

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    15,631,235

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,631,235

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.1%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    4


    CUSIP No. 00847G705    13G   

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal International Management S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    15,631,235

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    15,631,235

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,631,235

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.1%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    5


    CUSIP No. 00847G705    13G   

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal Group S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    15,631,235

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    15,631,235

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,631,235

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.1%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    6


    CUSIP No. 00847G705    13G   

     

    1   

    NAMES OF REPORTING PERSONS

     

    Westend S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    15,631,235

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    15,631,235

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,631,235

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.1%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    7


    CUSIP No. 00847G705    13G   

     

    1   

    NAMES OF REPORTING PERSONS

     

    Stichting Administratiekantoor Westend

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    The Netherlands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    15,631,235

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    15,631,235

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,631,235

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.1%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    8


    CUSIP No. 00847G705    13G   

     

    1   

    NAMES OF REPORTING PERSONS

     

    Mr. Amaury Wittouck

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Belgium

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    15,631,235

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    15,631,235

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,631,235

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.1%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    9


    Item 1(a).

    Name of Issuer:

    Agenus Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    3 Forbes Road, Lexington, MA 02421

     

    Item 2(a).

    Name of Person Filing:

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship:

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Bermuda limited partnership

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iii) Artal International S.C.A. (“Artal International”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg limited partnership

    (iv) Artal International Management S.A. (“Artal International Management”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (v) Artal Group S.A. (“Artal Group”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vi) Westend S.A. (“Westend”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vii) Stichting Administratiekantoor Westend (the “Stichting”)

    Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

    Citizenship: Netherlands foundation

    (viii) Mr. Amaury Wittouck

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Belgium

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.01 (the “Shares”)

     

    Item 2(e).

    CUSIP Number:

    00847G705

     

    10


    Item 3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    As of December 31, 2023, Invus Public Equities directly held 15,631,235 Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares held by Invus Public Equities. The Geneva branch of Artal International, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Artal International Management, as the managing partner of Artal International, controls Artal International and, accordingly, may be deemed to beneficially own the Shares that Artal International may be deemed to beneficially own. Artal Group, as the sole stockholder of Artal International Management, controls Artal International Management and, accordingly, may be deemed to beneficially own the Shares that Artal International Management may be deemed to beneficially own. Westend, as the parent company of Artal Group, controls Artal Group and, accordingly, may be deemed to beneficially own the Shares that Artal Group may be deemed to beneficially own. The Stichting, as the majority stockholder of Westend, controls Westend and, accordingly, may be deemed to beneficially own the Shares that Westend may be deemed to beneficially own. Mr. Wittouck, as the sole member of the board of the Stichting, controls the Stichting and, accordingly, may be deemed to beneficially own the Shares that the Stichting may be deemed to beneficially own.

    (b) Percent of class:

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on 381,495,471 Shares outstanding as of November 3, 2023 based on information provided by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

    (c) Number of shares as to which Invus Public Equities, Invus PE Advisors, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck has:

    (i) Sole power to vote or to direct the vote:

    15,631,235

    (ii) Shared power to vote or to direct the vote:

    0

    (iii) Sole power to dispose or to direct the disposition of:

    15,631,235

    (iv) Shared power to dispose or to direct the disposition of:

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of December 31, 2023 the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    11


    Item 8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    12


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 9, 2024

     

    INVUS PUBLIC EQUITIES, L.P.
    By:   INVUS PUBLIC EQUITIES ADVISORS, LLC, its general partner
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    INVUS PUBLIC EQUITIES ADVISORS, LLC
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    ARTAL INTERNATIONAL S.C.A.
    By:   ARTAL INTERNATIONAL MANAGEMENT S.A., its managing partner
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL INTERNATIONAL MANAGEMENT S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL GROUP S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Authorized Person


    WESTEND S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    STICHTING ADMINISTRATIEKANTOOR WESTEND
    By:  

    /s/ Amaury Wittouck

    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK

    /s/ Amaury Wittouck

    Get the next $AGEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AGEN

    DatePrice TargetRatingAnalyst
    6/4/2025$25.00Neutral → Buy
    H.C. Wainwright
    7/19/2024$35.00 → $8.00Outperform → Neutral
    Robert W. Baird
    7/18/2024Outperform → Mkt Perform
    William Blair
    7/18/2024$9.00Buy → Neutral
    H.C. Wainwright
    6/6/2023$8.00Outperform
    Robert W. Baird
    6/6/2023$60.00 → $80.00Outperform
    Robert W. Baird
    2/28/2023$8.00Buy
    H.C. Wainwright
    9/28/2022$5.00Outperform
    SMBC Nikko
    More analyst ratings

    $AGEN
    SEC Filings

    See more
    • Agenus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - AGENUS INC (0001098972) (Filer)

      6/20/25 4:10:27 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFR14A filed by Agenus Inc.

      DEFR14A - AGENUS INC (0001098972) (Filer)

      6/6/25 4:05:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AGENUS INC (0001098972) (Filer)

      6/4/25 4:37:44 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

      Agenus Inc. (NASDAQ:AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases (NLM). Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of the global BATTMAN Phase 3 trial. The FDA waived the need for a BOT monotherapy arm, allowing for a simple two-arm study design. These new BOT/BAL data were reported at the 2025 ESMO Ga

      7/7/25 8:55:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

      Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients are most likely to benefit from BOT/BAL treatment Collaboration builds on landmark 2024 Cancer Discovery study elucidating botensilimab's unique FcγR-mediated immune activation underlying activity in refractory tumors Supports AI-enabled biomarker discovery, aligning with the national priorities and the FDA to expand access to personalized cancer treatment Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomark

      6/17/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Announces Virtual Annual Shareholders Meeting

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests. Webcast Information: Date: Tuesday, June 17, 2025 Time: 10:30 a.m. ET A live webcast and replay

      6/10/25 1:30:00 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agenus upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Agenus from Neutral to Buy and set a new price target of $25.00

      6/4/25 7:30:33 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously

      7/19/24 7:27:15 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by William Blair

      William Blair downgraded Agenus from Outperform to Mkt Perform

      7/18/24 1:59:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Financials

    Live finance-specific insights

    See more
    • Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

      $75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M equity investment at $7.50 per share Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as "Zydus," designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics

      6/3/25 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Reports Q1 2025 Financial Results and Key Business Updates

      BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones Near-Term Capital Transaction Poised to Bolster Liquidity Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. "The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and

      5/12/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu

      4/29/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wright Timothy

      4 - AGENUS INC (0001098972) (Issuer)

      7/3/25 4:05:07 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Armen Garo H was granted 64,833 shares, increasing direct ownership by 33% to 258,842 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      6/30/25 4:30:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer O'Day Steven J was granted 43,497 shares, increasing direct ownership by 319% to 57,116 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      6/30/25 4:30:24 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Agenus Announces Appointment of Tom Harrison to Board of Directors

      Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

      8/8/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

      Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

      6/17/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Expands Executive Leadership Team

      Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

      7/20/23 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 7:58:18 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 9:21:26 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      6/10/24 12:15:17 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Armen Garo H bought $324,050 worth of shares (500,000 units at $0.65) (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      2/15/24 6:59:48 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiinberg Ulf bought $19,000 worth of shares (25,000 units at $0.76), increasing direct ownership by 25% to 124,063 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      11/17/23 4:22:11 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care